Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 553,940
  • Shares Outstanding, K 77,910
  • Annual Sales, $ 0 K
  • Annual Income, $ -174,330 K
  • EBIT $ -179 M
  • EBITDA $ -179 M
  • 60-Month Beta 2.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.13

Options Overview Details

View History
  • Implied Volatility 479.20% (+70.41%)
  • Historical Volatility 107.20%
  • IV Percentile 77%
  • IV Rank 36.79%
  • IV High 1,154.33% on 11/07/25
  • IV Low 86.30% on 06/16/25
  • Expected Move (DTE 20) 0.94 (13.27%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 422
  • Volume Avg (30-Day) 504
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 3,405
  • Open Int (30-Day) 5,899
  • Expected Range 6.17 to 8.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.41
  • Number of Estimates 7
  • High Estimate -0.35
  • Low Estimate -0.49
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +30.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.52 +28.71%
on 03/05/26
8.72 -18.46%
on 03/10/26
+0.90 (+14.49%)
since 02/27/26
3-Month
4.92 +44.51%
on 01/12/26
8.72 -18.46%
on 03/10/26
+1.27 (+21.75%)
since 12/26/25
52-Week
2.41 +195.02%
on 05/15/25
8.72 -18.46%
on 03/10/26
+2.74 (+62.70%)
since 03/27/25

Most Recent Stories

More News
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

-  Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003...

SLDB : 7.11 (-8.02%)
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex...

SLDB : 7.11 (-8.02%)
Solid Biosciences Announces Oversubscribed $240 Million Private Placement

CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today...

SLDB : 7.11 (-8.02%)
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today...

SLDB : 7.11 (-8.02%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...

SLDB : 7.11 (-8.02%)
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design - - IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - -...

SLDB : 7.11 (-8.02%)
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...

SLDB : 7.11 (-8.02%)
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

-  Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation...

SLDB : 7.11 (-8.02%)
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected...

SLDB : 7.11 (-8.02%)
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...

SLDB : 7.11 (-8.02%)

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

3rd Resistance Point 8.54
2nd Resistance Point 8.23
1st Resistance Point 7.67
Last Price 7.11
1st Support Level 6.80
2nd Support Level 6.49
3rd Support Level 5.93

See More

52-Week High 8.72
Last Price 7.11
Fibonacci 61.8% 6.31
Fibonacci 50% 5.57
Fibonacci 38.2% 4.82
52-Week Low 2.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.